Next Article in Journal
A Novel Role for the Tumor Suppressor Gene ITF2 in Tumorigenesis and Chemotherapy Response
Next Article in Special Issue
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
Previous Article in Journal
Role of BET Inhibitors in Triple Negative Breast Cancers
Previous Article in Special Issue
A Novel Comprehensive Clinical Stratification Model to Refine Prognosis of Glioblastoma Patients Undergoing Surgical Resection
 
 
Brief Report

Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer

1
Laboratory of Medical Oncology, Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
2
Department of Medical Oncology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Korea
3
Department of Laboratory Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Korea
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(4), 785; https://doi.org/10.3390/cancers12040785
Received: 1 March 2020 / Revised: 23 March 2020 / Accepted: 24 March 2020 / Published: 26 March 2020
(This article belongs to the Special Issue Precision Medicine in Solid Tumors)
Epidermal growth factor receptor (EGFR) mutation testing is essential for individualized treatment using tyrosine kinase inhibitors. We evaluated two EGFR mutation tests, cobas v2 and PANAMutyper, for detection of EGFR activating mutations Ex19del, L858R, and T790M in tumor tissue and plasma from 244 non-small cell lung cancer (NSCLC) patients. The Kappa coefficient (95% CI) between the tests was 0.82 (0.74–0.92) in tumor samples (suggesting almost perfect agreement) and 0.69 (0.54–0.84) in plasma (suggesting substantial agreement). In plasma samples, both tests showed low to moderate sensitivity depending on disease stage but high diagnostic precision (86%–100%) in all disease stages (sensitivity: percentage of mutations in tumors that are also detected in plasma; precision: percentage of mutations in plasma which are also detected in tumors). Among the 244 patients, those previously diagnosed as T790M carriers who received osimertinib treatment showed dramatically better clinical outcomes than T790M carriers without osimertinib treatment. Taken together, our study supports interchangeable use of cobas v2 and PANAMutyper in tumor and plasma EGFR testing. Both tests have high diagnostic precision in plasma but are particularly valuable in late-stage disease. Our clinical data in T790M carriers strongly support the clinical benefits of osimertinib treatment guided by both EGFR mutation tests. View Full-Text
Keywords: circulating free DNA; liquid biopsy; epidermal growth factor receptor; tyrosine kinase inhibitor; osimertinib circulating free DNA; liquid biopsy; epidermal growth factor receptor; tyrosine kinase inhibitor; osimertinib
Show Figures

Figure 1

MDPI and ACS Style

Kim, J.-O.; Shin, J.-Y.; Kim, S.R.; Shin, K.S.; Kim, J.; Kim, M.-Y.; Lee, M.-R.; Kim, Y.; Kim, M.; Hong, S.H.; Kang, J.H. Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer. Cancers 2020, 12, 785. https://doi.org/10.3390/cancers12040785

AMA Style

Kim J-O, Shin J-Y, Kim SR, Shin KS, Kim J, Kim M-Y, Lee M-R, Kim Y, Kim M, Hong SH, Kang JH. Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer. Cancers. 2020; 12(4):785. https://doi.org/10.3390/cancers12040785

Chicago/Turabian Style

Kim, Jeong-Oh, Jung-Young Shin, Seo Ree Kim, Kab Soo Shin, Joori Kim, Min-Young Kim, Mi-Ran Lee, Yonggoo Kim, Myungshin Kim, Sook Hee Hong, and Jin Hyoung Kang. 2020. "Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer" Cancers 12, no. 4: 785. https://doi.org/10.3390/cancers12040785

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop